RxDoctor Payments Data

Jennie Gardner, APRN

Family · Frenchburg, KYNPI 1790869071

Payments from drug & device makers

$3,129in general payments, 2019–2025

Across 188 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$485
  • GSK$323
  • Novo Nordisk$317
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$292
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$210
  • Teva Pharmaceuticals USA, Inc.$192
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$3,08499%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,129 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$34,700
Medicare patients
87
Services billed
921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$38,878
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$35,270
EliquisApixaban42$26,182
OzempicSemaglutide16$24,367
FarxigaDapagliflozin Propanediol16$18,649
RybelsusSemaglutide15$14,267
GemtesaVibegron12$7,654
SymbicortBudesonide/Formoterol Fumarate19$4,726
Albuterol Sulfate HfaAlbuterol Sulfate65$1,951
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,639
Oxcarbazepine15$1,328
Levothyroxine Sodium185$1,236
Ventolin HfaAlbuterol Sulfate22$1,222
Atorvastatin Calcium144$916
Pravastatin Sodium61$800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$151$38,87849 claims
Novo NordiskOzempic, Rybelsus$317$38,63431 claims
GSKTrelegy Ellipta$323$35,27036 claims
PfizerEliquis$29$26,18242 claims
AstraZenecaFarxiga, Symbicort$43$23,37535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.

Other family in Frenchburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →